Peptide Comparison
AHK-Cu vs Pentapeptide-18
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
AHK-Cu and Pentapeptide-18 share the cosmetic class and carry roughly equivalent evidence (Cosmetic Clinical Studies / Cosmetic Clinical Studies). The catalogued data does not favor one over the other; pick based on practical fit: route, dosing schedule, cost, regulatory framing, or which specific receptor sub-target matters most for the intended research use.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| AHK-Cu | Pentapeptide-18 | |
|---|---|---|
| Class | Copper tripeptide (cosmetic) | Cosmetic peptide; enkephalin mimetic |
| Drug class | Dermatologic | Dermatologic |
| Mechanism | Copper delivery to hair follicles; angiogenesis and VEGF induction in scalp | Enkephalin mimetic; modulates SNAP-25 at muscle-neuron interface (topical) |
| Route | Topical | Topical |
| Half-life | Topical (no systemic) | Topical |
| Dosage (research) | Topical 0.01-0.1% | Topical 2-10% |
| Evidence tier | Cosmetic Clinical Studies | Cosmetic Clinical Studies |
| Research depth | 3 indexed | 11 indexed |
| Availability | Cosmetic | Cosmetic |
| Reported risks | Skin irritation; theoretical copper issues | Minimal |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick AHK-Cu or Pentapeptide-18?
AHK-Cu and Pentapeptide-18 share the cosmetic class and carry roughly equivalent evidence (Cosmetic Clinical Studies / Cosmetic Clinical Studies). The catalogued data does not favor one over the other; pick based on practical fit: route, dosing schedule, cost, regulatory framing, or which specific receptor sub-target matters most for the intended research use.
What is the difference between AHK-Cu and Pentapeptide-18?
AHK-Cu is classed as Copper tripeptide (cosmetic); Pentapeptide-18 is classed as Cosmetic peptide; enkephalin mimetic. Reported mechanism: AHK-Cu, Copper delivery to hair follicles; angiogenesis and VEGF induction in scalp; Pentapeptide-18, Enkephalin mimetic; modulates SNAP-25 at muscle-neuron interface (topical). Reported half-life: AHK-Cu, Topical (no systemic); Pentapeptide-18, Topical. Routes in published studies: AHK-Cu, Topical; Pentapeptide-18, Topical.
Which has stronger evidence, AHK-Cu or Pentapeptide-18?
AHK-Cu and Pentapeptide-18 sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. AHK-Cu is graded Cosmetic Clinical Studies, with 3 cited sources on its reference page and 3 indexed studies. Pentapeptide-18 is graded Cosmetic Clinical Studies, with 3 cited sources on its reference page and 11 indexed studies.
Which is more accessible, AHK-Cu or Pentapeptide-18?
Neither AHK-Cu nor Pentapeptide-18 is an FDA-approved drug. Catalog status: AHK-Cu, Cosmetic; Pentapeptide-18, Cosmetic.
Are AHK-Cu and Pentapeptide-18 ever combined?
AHK-Cu and Pentapeptide-18 appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…